Sagittal Pharma Consulting
Essjay & Sagittal 2026 Offsite: Regulatory Updates
44:33
Sagittal Pharma Consulting
Essjay & Sagittal 2026 Offsite: AI Update
44:19
Sagittal Pharma Consulting
Essjay & Sagittal 2026 Offsite: ICH GCP E6 (R3): Risk Expectations vs Reality
53:42
Sagittal Pharma Consulting
Essjay & Sagittal 2026 Offsite: CIOMS Benefit Risk Framework
55:50
Sagittal Pharma Consulting
R3 Taster Webinar
17:29
Sagittal Pharma Consulting
AI/ChatGPT: Everything you wanted to know but were afraid to ask!
27:37
Sagittal Pharma Consulting
How to Manage Global LSO/Local QPPV Requirements
28:57
Sagittal Pharma Consulting
Globalisation of QP Requirements
32:09
Sagittal Pharma Consulting
QPPV and local requirements
32:09
Sagittal Pharma Consulting
Unlock the Secrets of the EU Marketing Authorization Application
29:48
Sagittal Pharma Consulting
Risk Minimisation
28:20
Sagittal Pharma Consulting
Tip tips for report writing in pharmacovigilance
36:24
Sagittal Pharma Consulting
Signal Detection in PV
32:41
Sagittal Pharma Consulting
Literature Monitoring and Review
36:47
Sagittal Pharma Consulting
Post Authorisation Safety
36:17
Sagittal Pharma Consulting
Medication Errors
33:50
Sagittal Pharma Consulting
Device Vigilance in PV
37:02
Sagittal Pharma Consulting
GVP Modules
36:39
Sagittal Pharma Consulting
The Importance of the Quality Management System
36:57
Sagittal Pharma Consulting
Types of pharmacoepidemiological studies and what their biases may be
33:53
Sagittal Pharma Consulting
Causality Assessments
32:21
Sagittal Pharma Consulting
Compliant & Effective Market Research Results
22:10
Sagittal Pharma Consulting
Understanding the GVP Module V
40:24
Sagittal Pharma Consulting
Advisory Board Meeting
18:15
Sagittal Pharma Consulting
Signal Detection and Eudravigilance
43:41
Sagittal Pharma Consulting
Case Processing and Eudravigilance
43:58
Sagittal Pharma Consulting
Reference Safety Information
33:25